Atlas Trials

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

Clinical trial NCT05171335 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT05171335
Sponsor
The Methodist Hospital Research Institute
Status
ENROLLING_BY_INVITATION
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2022-06-20
Primary completion
2026-06-30
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.